Cetera Investment Advisers Buys New Shares in Xeris Biopharma Holdings, Inc. $XERS

Cetera Investment Advisers bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 44,597 shares of the company’s stock, valued at approximately $245,000.

Other hedge funds have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC boosted its position in Xeris Biopharma by 92.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company’s stock worth $172,000 after purchasing an additional 14,986 shares during the period. Millennium Management LLC boosted its position in Xeris Biopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock worth $6,606,000 after purchasing an additional 502,853 shares during the period. Two Sigma Advisers LP bought a new position in Xeris Biopharma during the fourth quarter worth $47,000. Raymond James Financial Inc. bought a new position in Xeris Biopharma during the fourth quarter worth $45,000. Finally, New York State Common Retirement Fund boosted its position in Xeris Biopharma by 90.3% during the first quarter. New York State Common Retirement Fund now owns 43,422 shares of the company’s stock worth $238,000 after purchasing an additional 20,600 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

XERS opened at $7.59 on Friday. The firm has a market cap of $1.23 billion, a P/E ratio of -36.14 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 52-week low of $2.48 and a 52-week high of $7.79. The business’s fifty day moving average is $5.47 and its 200-day moving average is $4.82.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analyst estimates of $64.58 million. On average, research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In related news, Director John Johnson sold 107,500 shares of the company’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total transaction of $786,900.00. Following the completion of the sale, the director directly owned 833,483 shares in the company, valued at $6,101,095.56. This represents a 11.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Dawn Halkuff sold 42,500 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total value of $309,400.00. Following the sale, the director owned 115,000 shares of the company’s stock, valued at approximately $837,200. This represents a 26.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.47% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have commented on XERS. HC Wainwright began coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They set a “buy” rating and a $10.00 price objective for the company. Oppenheimer increased their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Finally, Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.58.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.